Helicobacter pylori eradication: influence of interleukin-1beta –31 C/T polymorphism

Tássia Flores Rech, Luiz Edmundo Mazzoleni, Felipe Mazzoleni, Carlos Fernando de Magalhães Francesconi, Guilherme Becker Sander, Rafael Tomoya Michita, Débora Dreher Nabinger, Tobias Cancian Milbradt, Ronaldo João Spinato Torresini, Daniel Simon

To analyze the influence of the -31 C/T polymorphism of the interleukin-1β gene on Helicobacter pylori eradication therapy success in patients with functional dyspepsia. Functional dyspepsia was diagnosed according to the Rome III criteria. All patients underwent upper gastrointestinal endoscopy, and gastric biopsies were obtained at screening and 12 months after randomization (last follow-up visit). Urease test and histological examination were performed to define the H. pylori status. Patients received twice-daily amoxicillin, clarithromycin and omeprazole for 10 days. Genotyping of the IL1B -31 C/T polymorphism (rs1143627) was performed using polymerase chain reaction-restriction fragment length polymorphism. One hundred forty-nine patients received treatment with triple therapy for H. pylori eradication. Only one patient was lost to follow-up, and adherence to study medication was 94.6%. A total of 148 patients (mean age 46.08 ± 12.24 years; 81.8% women) were evaluated for the influence of the IL1B -31 C/T polymorphism on the outcome of H. pylori eradication therapy. After treatment, bacteria were eradicated in 87% of patients (129/148). Genotype frequencies of the IL1B -31 C/T polymorphism were as follows: CC, 38/148 (25.7%); CT, 71/148 (47.9%); and TT, 39/148 (26.4%). Successful eradication rate was 78.9%, 94.4% and 82.1% for the CC, CT and TT genotypes, respectively. The CT genotype was significantly associated with successful H. pylori eradication (p = 0.039). This study suggests that the CT genotype of the IL1B -31 C/T polymorphism plays a role in the successful eradication of H. pylori among patients with functional dyspepsia.